An Open Label Study to Evaluate the Effect on Bone Mineral Density, and the Safety, of Quarterly Intravenous Bonviva in Patients With Post-menopausal Osteoporosis.
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Expanded access; Therapeutic Use
- Sponsors Roche
- 18 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jan 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 21 Jul 2009 Planned end date (Oct 2008) added as reported by ClinicalTrials.gov.